bluebird bio, Inc. (0HOH.L)

0,9499 -0,0355 (-3,60%) In data: 02:57PM BST. Mercato aperto.

bluebird bio, Inc.

455 Grand Union Boulevard
Somerville, MA 02145
United States
339 499 9300
https://www.bluebirdbio.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 323

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Andrew Obenshain	President, CEO & Director	1,04M	N/D	1974
Mr. Thomas J. Klima	Chief Commercial Officer & COO	654,97k	N/D	1972
Mr. Richard A. Colvin M.D., Ph.D.	Chief Medical Officer	696,24k	N/D	1966
Mr. Christopher Krawtschuk CPA	CFO, Principal Accounting Officer & Treasurer	N/D	N/D	1974
Mr. Joseph D. Vittiglio Esq., J.D.	Chief Legal & Business Officer and Secretary	N/D	N/D	1972
Jess Rowlands	Head of Corporate Communications	N/D	N/D	N/D
Ms. Andrea Walton	Chief People Officer	N/D	N/D	N/D
Mr. Kasra Kasraian	Senior Vice President of Technical Development & Operations	N/D	N/D	N/D
Mr. Scott Shoemaker	Senior Vice President of Quality	N/D	N/D	N/D
Ms. Sarah Alspach	Senior Vice President of External Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di bluebird bio, Inc. al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 3; diritti degli azionisti: 5; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.